AstraZeneca Shares Drop After Heart Drug Trial Failure

AstraZeneca's shares plummeted by over 9%, wiping out more than £20 billion in market value, after its heart disease treatment failed to meet its primary efficacy goal in a clinical trial. This marks a rare trial failure for the pharmaceutical giant.

9 Jul, 07:35 — 9 Jul, 13:45

Post Share

Why this matters

This story matters because AstraZeneca is a major pharmaceutical company, and the failure of a late-stage drug trial can have significant financial implications for the company and its investors. It also impacts the potential availability of new treatments for heart disease, a leading cause of death globally.

Key entitiesAstraZeneca Wainua

The Story

What 6 sources agree on, dispute, and miss

What sources agree on

AstraZeneca's shares dropped following a disappointing drug trial
The drug involved is named Wainua
Wainua failed to meet its main goal of reducing cardiovascular deaths in the trial

Key claims2 agreed · 1 unverified

AstraZeneca's stock market value slumped by more than £20bn

unverified·The Independent

✓

AstraZeneca's shares slid 9%

agreed·FTcnbc

✓

The Wainua drug failed to meet a goal to reduce deaths related to heart disease

agreed·The Independentseeking-alphaFTcnbc

Coverage gaps

The specific monetary value of AstraZeneca's stock market slump (£20bn)

ReportedThe Independent

Missingseeking-alphaFTcnbc

The Story

Analyzing sources…

Source Diversity

High (71/100)

6 sources33/33

Spectrum spread— 4/5 buckets covered25/33

Far L1

Far Left (1)

The Independent

Left2

Left (2)

newsbeastcnbc

Center2

Center (2)

bloombergFT

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 3 regions13/34

US3UK2Greece1

Political spectrum

LeftCenterRight

independent

cnbc

seeking-alpha

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

The Independentcenter-leftcenter-leftneutralMostly Factualfocused on financial impact, factual reporting

cnbccentercenter-leftneutralMostly Factualstraightforward reporting on stock drop and trial

Coverage leans: balanced

The coverage from all outlets is largely neutral and factual, focusing on the financial and scientific aspects of the story without apparent political framing.